Aslam Jivani
Pulmonary Disease · Elmhurst, NYNPI 1750392411
Payments from drug & device makers
Across 1,032 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- Regeneron Healthcare Solutions, Inc.$1K
- Amgen$1K
- Actelion Pharmaceuticals US, Inc.$970
- plus $10K from 44 others
What the payments were for
- Food & beverage$21,88498%
- Education$3712%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$375
How this compares
$22,255 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 724 | $763,039 |
| OfevNintedanib Esylate | 20 | $605,147 |
| XolairOmalizumab | 56 | $426,294 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 379 | $393,568 |
| Dupixent SyringeDupilumab | 36 | $180,502 |
| Breo ElliptaFluticasone/Vilanterol | 284 | $170,945 |
| AdempasRiociguat | 11 | $162,392 |
| NucalaMepolizumab | 27 | $158,568 |
| FarxigaDapagliflozin Propanediol | 135 | $150,106 |
| FasenraBenralizumab | 26 | $150,012 |
| TezspireTezepelumab-Ekko | 11 | $144,180 |
| EliquisApixaban | 88 | $108,141 |
| LinzessLinaclotide | 119 | $104,404 |
| OzempicSemaglutide | 48 | $85,661 |
| Spiriva RespimatTiotropium Bromide | 72 | $83,956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Incruse Ellipta, Arnuity Ellipta | $3,830 | $1,230,4071,349 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Fasenra, Tezspire, Symbicort | $3,425 | $891,412674 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Jardiance | $2,098 | $767,015149 claims |
| AbbVieLinzess, Ubrelvy, Vraylar | $239 | $143,485154 claims |
| PfizerEliquis, Nurtec Odt | $235 | $134,825101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $444 | $116,28259 claims |
| Novo NordiskOzempic, Rybelsus | $798 | $110,29961 claims |
| MerckJanuvia, Janumet, Dulera | $446 | $110,104128 claims |
| NovartisEntresto | $591 | $28,45423 claims |
| Optinose US, Inc.Xhance | $164 | $13,98912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Elmhurst
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.